NRXP NRx Pharmaceuticals, Inc.
Price Chart
Executive Summary
NRx Pharmaceuticals priced an underwritten public offering of 5,714,286 shares at $3.50/share, with gross proceeds of ~$20.0M ($23.0M if underwriters fully exercise the 30-day option). The offering is dilutive (~11% of pre-offering shares) and proceeds are for working capital and general corporate purposes. The stock closed at $3.50 on June 3, 2026, indicating no premium/discount at pricing.
Key Financial Metrics
Actionable Insight
The dilutive offering (~11% share count increase) is a near-term negative for existing shareholders, though the cash infusion supports the company's clinical pipeline. Monitor for any subsequent updates on NRX-100/NRX-101 regulatory progress, as the stock's prior strong performance (+35% avg T+20 alpha) suggests high sensitivity to pipeline catalysts.
Key Facts
- Pricing of 5,714,286 shares at $3.50 per share
- Gross proceeds of approximately $20.0 million ($23.0 million if option exercised)
- Underwriters granted 30-day option to purchase up to 857,142 additional shares
- Offering expected to close June 4, 2026
- Proceeds for working capital and general corporate purposes
- BTIG, LLC is lead bookrunning manager; Lucid Capital Markets is joint bookrunning manager
- Offering made under effective shelf registration statement on Form S-3 (File No. 333-288205)
Financial Impact
~$20M gross proceeds from sale of ~5.7M shares, representing approximately 11% dilution based on pre-offering share count (implied by market cap of $167M and price of $3.50 = ~47.7M shares pre-offering).
Risk Factors
- Dilution of ~11% for existing shareholders
- Proceeds used for working capital, not specific pipeline milestone, signaling potential cash burn concerns
- Clinical-stage biopharma with no approved products; regulatory setbacks could severely impact valuation
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
1d ago
|
Press Release
| $4.12 awaiting T+1 | awaiting T+1 | — | $4.14 (+0.49%) |
|
Jun 4, 2026
2d ago
|
Press Release
| $4.05 awaiting T+1 | awaiting T+1 | — | $4.14 (−2.22%) |
|
Jun 3, 2026
3d ago
|
Press Release
| $4.05 $4.05 | · 0.00% | ▲ +0.40% | $4.14 (−2.22%) |
|
Jun 2, 2026
4d ago
|
Press Release
| $4.05 $4.05 | · 0.00% | ▲ +0.41% | $4.14 (−2.22%) |
|
May 18, 2026
19d ago
|
Press Release
| $3.12 $3.03 | ▼ −2.73% | ▼ −2.08% | $4.14 (+32.91%) |
|
May 14, 2026
23d ago
|
Press Release
| $3.21 $3.28 | ▲ +2.18% | ▲ +3.41% | $4.14 (+28.97%) |
|
Mar 30, 2026
9w ago
|
Press Release
| $2.09 $2.13 | ▲ +1.91% | ▼ −0.98% | $4.14 (+98.09%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $1.84 $1.85 | ▲ +0.54% | ▲ +2.29% | $4.14 (+125.00%) |
|
Feb 24, 2026
14w ago
|
DEFA14A
| $1.91 $1.93 | ▲ +1.05% | ▲ +1.59% | $4.14 (+116.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access